Fasugba Oyebola, Gardner Anne, Mitchell Brett G, Mnatzaganian George
Faculty of Health Sciences, Australian Catholic University, 223 Antill Street, Watson, Australian Capital Territory, 2602, Australia.
Faculty of Arts, Nursing and Theology, Avondale College of Higher Education, 185 Fox Valley Road, Wahroonga, New South Wales, 2076, Australia.
BMC Infect Dis. 2015 Nov 25;15:545. doi: 10.1186/s12879-015-1282-4.
During the last decade the resistance rate of urinary Escherichia coli (E. coli) to fluoroquinolones such as ciprofloxacin has increased. Systematic reviews of studies investigating ciprofloxacin resistance in community- and hospital-acquired E. coli urinary tract infections (UTI) are absent. This study systematically reviewed the literature and where appropriate, meta-analysed studies investigating ciprofloxacin resistance in community- and hospital-acquired E. coli UTIs.
Observational studies published between 2004 and 2014 were identified through Medline, PubMed, Embase, Cochrane, Scopus and Cinahl searches. Overall and sub-group pooled estimates of ciprofloxacin resistance were evaluated using DerSimonian-Laird random-effects models. The I(2) statistic was calculated to demonstrate the degree of heterogeneity. Risk of bias among included studies was also investigated.
Of the identified 1134 papers, 53 were eligible for inclusion, providing 54 studies for analysis with one paper presenting both community and hospital studies. Compared to the community setting, resistance to ciprofloxacin was significantly higher in the hospital setting (pooled resistance 0.38, 95% CI 0.36-0.41 versus 0.27, 95% CI 0.24-0.31 in community-acquired UTIs, P < 0.001). Resistance significantly varied by region and country with the highest resistance observed in developing countries. Similarly, a significant rise in resistance over time was seen in studies reporting on community-acquired E. coli UTI.
Ciprofloxacin resistance in E. coli UTI is increasing and the use of this antimicrobial agent as empirical therapy for UTI should be reconsidered. Policy restrictions on ciprofloxacin use should be enhanced especially in developing countries without current regulations.
在过去十年中,尿路大肠杆菌(E. coli)对环丙沙星等氟喹诺酮类药物的耐药率有所上升。目前尚无关于社区获得性和医院获得性大肠杆菌尿路感染(UTI)中环丙沙星耐药性研究的系统评价。本研究系统回顾了相关文献,并在适当情况下对社区获得性和医院获得性大肠杆菌UTI中环丙沙星耐药性的研究进行了荟萃分析。
通过检索Medline、PubMed、Embase、Cochrane、Scopus和Cinahl数据库,确定2004年至2014年发表的观察性研究。使用DerSimonian-Laird随机效应模型评估环丙沙星耐药性的总体和亚组汇总估计值。计算I(2)统计量以显示异质性程度。还对纳入研究的偏倚风险进行了调查。
在检索到的1134篇论文中,53篇符合纳入标准,提供了54项研究进行分析,其中一篇论文同时包含社区和医院研究。与社区环境相比,医院环境中环丙沙星的耐药性显著更高(汇总耐药率0.38,95%CI 0.36 - 0.41,而社区获得性UTI为0.27,95%CI 0.24 - 0.31,P < 0.001)。耐药性因地区和国家而异,在发展中国家观察到的耐药性最高。同样,在报告社区获得性大肠杆菌UTI的研究中,耐药性随时间显著上升。
大肠杆菌UTI中环丙沙星耐药性正在增加,应重新考虑将这种抗菌药物作为UTI经验性治疗的使用。应加强对环丙沙星使用的政策限制,特别是在没有现行法规的发展中国家。